We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Fuels Growth via Market Expansion and New Care Verticals
Read MoreHide Full Article
Key Takeaways
HIMS reached 2.4 million subscribers in Q2 2025, supported by nearly 1,500 licensed healthcare providers.
HIMS is expanding into menopause and low testosterone care to tap large U.S. hormonal health markets.
HIMS' ZAVA deal adds 1.3 million EU patients; Canada launch to follow with generic semaglutide in 2026.
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , is building its market opportunity around democratizing access to personalized healthcare, particularly in areas that have historically been underserved. By the second quarter of 2025, the platform had grown to 2.4 million subscribers supported by nearly 1,500 licensed providers. Its weight loss specialty, anchored in GLP-1 treatments, highlights the strength of its model, delivering retention rates above industry averages thanks to continuous provider engagement and integrated digital support.
Hims & Hers is preparing to expand further into hormonal health with offerings that target menopause and low testosterone, conditions representing a large U.S. market opportunity. Integrated lab testing and a broader shift toward longevity and preventive care are expected to increase patient lifetime value while positioning it as more than just a treatment provider. Instead, HIMS aims to play a role in long-term health optimization and proactive care.
International expansion is another powerful growth driver. The acquisition of ZAVA extends Hims & Hers’ footprint across the U.K., Germany, France and Ireland, granting immediate access to more than 1.3 million existing patients and strengthening its position as a global digital health leader. Planned entry into Canada in 2026, aligned with the introduction of generic semaglutide, will likely make weight loss treatments significantly more affordable and accessible for a population where obesity rates remain high. Together, vertical integration, entry into new therapeutic categories and global expansion underscore Hims & Hers’ capacity to sustain momentum and capture long-term market share.
LFMD & AMWL’s Market Opportunities and Growth Drivers
LifeMD, Inc.’s (LFMD - Free Report) market opportunity centers on scaling a vertically integrated, subscription telehealth platform across primary care and lifestyle conditions. LFMD is adding commercial insurance and Medicare coverage pathways, expanding reach and conversion. Growth drivers include LifeMD’s owned pharmacy with planned non-sterile compounding, enabling cost and fulfillment control, a GLP-1 weight-management program with tens of thousands of subscribers and B2B partnerships for at-home labs and remote monitoring (Ash Wellness, Withings) that deepen personalization and retention. LifeMD’s telehealth revenues grew 29.7% year over year in second-quarter 2025, underscoring sustained demand.
American Well Corporation’s (AMWL - Free Report) , popularly known as Amwell, market opportunity is tied to enterprise, payer and government modernization of care. Amwell’s platform powers the Military Health System’s virtual visits worldwide, replacing MHS Video Connect. This change has nearly tripled virtual visit volumes. A one-year extension sustains this presence across about 9.6 million beneficiaries. Amwell’s growth drivers include increasing subscription software mix, new wins like Florida Blue and AI-enabled efficiency as it targets positive operating cash flow in 2026. Amwell continues positioning as a unified, tech-enabled care platform for large systems.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 86.5% year to date, outperforming the industry’s growth of 23.5%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 3.8X is lower than the industry’s average of 5.8X, but is higher than its three-year median of 2.4X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 137% improvement from 2024.
Image: Bigstock
Hims & Hers Fuels Growth via Market Expansion and New Care Verticals
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , is building its market opportunity around democratizing access to personalized healthcare, particularly in areas that have historically been underserved. By the second quarter of 2025, the platform had grown to 2.4 million subscribers supported by nearly 1,500 licensed providers. Its weight loss specialty, anchored in GLP-1 treatments, highlights the strength of its model, delivering retention rates above industry averages thanks to continuous provider engagement and integrated digital support.
Hims & Hers is preparing to expand further into hormonal health with offerings that target menopause and low testosterone, conditions representing a large U.S. market opportunity. Integrated lab testing and a broader shift toward longevity and preventive care are expected to increase patient lifetime value while positioning it as more than just a treatment provider. Instead, HIMS aims to play a role in long-term health optimization and proactive care.
International expansion is another powerful growth driver. The acquisition of ZAVA extends Hims & Hers’ footprint across the U.K., Germany, France and Ireland, granting immediate access to more than 1.3 million existing patients and strengthening its position as a global digital health leader. Planned entry into Canada in 2026, aligned with the introduction of generic semaglutide, will likely make weight loss treatments significantly more affordable and accessible for a population where obesity rates remain high. Together, vertical integration, entry into new therapeutic categories and global expansion underscore Hims & Hers’ capacity to sustain momentum and capture long-term market share.
LFMD & AMWL’s Market Opportunities and Growth Drivers
LifeMD, Inc.’s (LFMD - Free Report) market opportunity centers on scaling a vertically integrated, subscription telehealth platform across primary care and lifestyle conditions. LFMD is adding commercial insurance and Medicare coverage pathways, expanding reach and conversion. Growth drivers include LifeMD’s owned pharmacy with planned non-sterile compounding, enabling cost and fulfillment control, a GLP-1 weight-management program with tens of thousands of subscribers and B2B partnerships for at-home labs and remote monitoring (Ash Wellness, Withings) that deepen personalization and retention. LifeMD’s telehealth revenues grew 29.7% year over year in second-quarter 2025, underscoring sustained demand.
American Well Corporation’s (AMWL - Free Report) , popularly known as Amwell, market opportunity is tied to enterprise, payer and government modernization of care. Amwell’s platform powers the Military Health System’s virtual visits worldwide, replacing MHS Video Connect. This change has nearly tripled virtual visit volumes. A one-year extension sustains this presence across about 9.6 million beneficiaries. Amwell’s growth drivers include increasing subscription software mix, new wins like Florida Blue and AI-enabled efficiency as it targets positive operating cash flow in 2026. Amwell continues positioning as a unified, tech-enabled care platform for large systems.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 86.5% year to date, outperforming the industry’s growth of 23.5%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 3.8X is lower than the industry’s average of 5.8X, but is higher than its three-year median of 2.4X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 137% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.